The purpose of this study was to evaluate the pharmacokinetics of intranasal ... and 3.38 μg/L for treatments B and C, respectively. Mean (% coefficient of variation) bioavailability of ...

Rigel Pharmaceuticals, Inc. RIGL is set to report its fourth-quarter and full-year 2024 earnings on March 4. The Zacks ...

Head-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetics in healthy human subjects ...

PMN310 is a humanized monoclonal antibody (mAb) designed and developed to selectively target only soluble amyloid-beta ...

Proof of Rovi’s commitment to a sustainable business model is the recognition obtained by the company through the evaluation by Sustainalytics. In December 2024, Rovi obtained the fifth position in ...

The FDA has approved the BLA for Ospomyv™ and Xbryk™, biosimilars to Prolia (denosumab) and Xgeva (denosumab), respectively.

Advisor engaged in evaluating strategic options to maximize shareholder valueCash balance of $76.6 million as of December 31, 2024UTRECHT, The ...

NXP800 Phase 1b study in patients with platinum resistant, ARID1a-mutated ovarian cancer is ongoing; Orphan Drug Designation granted by the U.S.

Objective: Spalt-Liqua® is a newsoft gelatin capsule containing 200mg of totally dissolved ibuprofen as the active ingredient. The primary objective of the study was to assess bioequivalence ...

Arrowhead Pharmaceuticals, Inc. today announced preclinical results on ARO-ALK7, the company's investigational RNA interference (RNAi) therapeutic targeting Activin receptor-like kinase 7 (ALK7) being ...

PEC (Peak Eosinophil Count) is reported as peak reduction across a standard number of biopsy sites in the treatment area and remission rate is the percentage of biopsy ...